The combination of different ICIs, such as PD-1/PD-L1 inhibitors with CTLA-4 inhibitors, can simultaneously block multiple immune checkpoints, potentially leading to a more comprehensive activation of the immune system against the tumor. Here, RPL17 is linked to neoplasm.